Skog Johan
Umea University, Department of Virology, SE-901 85, Umea, Sweden.
Expert Rev Vaccines. 2006 Dec;5(6):793-802. doi: 10.1586/14760584.5.6.793.
This review describes glioma-specific antigens important in immunotherapy of glioma tumors. The structure and function of these antigens and recent immunotherapy data are summarized. Also, some important aspects of tumor formation are outlined. The roles of neuronal precursor cells and tumor stroma cells are discussed. The stroma cells of the tumor may be of interest as a target for tumor therapy, especially since they are less heterogeneous than the tumor cells. To date, the clinical benefit of immunotherapy has been very limited. Immunotherapy is, however, still an extremely promising approach to tumor therapy and it will most likely be implemented as a future treatment option for many types of tumors. The current shortcomings of immunotherapy will probably diminish as we start to understand and are able to modulate tumor-induced immunosuppression. There is also a need for a continued search for new tumor-specific antigens and to optimize protocols for vaccine administration.
本综述描述了在胶质瘤肿瘤免疫治疗中重要的胶质瘤特异性抗原。总结了这些抗原的结构和功能以及近期的免疫治疗数据。此外,还概述了肿瘤形成的一些重要方面。讨论了神经前体细胞和肿瘤基质细胞的作用。肿瘤的基质细胞作为肿瘤治疗的靶点可能会受到关注,特别是因为它们比肿瘤细胞的异质性更低。迄今为止,免疫治疗的临床益处非常有限。然而,免疫治疗仍然是一种极具前景的肿瘤治疗方法,很可能会成为未来多种类型肿瘤的治疗选择。随着我们开始理解并能够调节肿瘤诱导的免疫抑制,免疫治疗目前的缺点可能会减少。还需要继续寻找新的肿瘤特异性抗原,并优化疫苗接种方案。